Robert W. Wilkinson, Ph.D. Email & Phone Number
Who is Robert W. Wilkinson, Ph.D.? Overview
A concise factual answer block for searchers comparing this professional profile.
Robert W. Wilkinson, Ph.D. is listed as Vice President, Head of Oncology Research at Immunocore I Focus on Immunotherapies I Passionate about science and delivering better medicines for cancer patients at Immunocore, based in Greater Cambridge Area, United Kingdom, United Kingdom. AeroLeads shows a matched LinkedIn profile for Robert W. Wilkinson, Ph.D..
Robert W. Wilkinson, Ph.D. previously worked as Vice President, Head of Oncology Research at Immunocore and Executive Director, Global Head of NextGen Immuno-Oncology (IO) at Astrazeneca. Robert W. Wilkinson, Ph.D. holds Doctor Of Philosophy - Phd, Experimental Immunology from University Of Birmingham.
Email format at Immunocore
This section adds company-level context without repeating Robert W. Wilkinson, Ph.D.'s masked contact details.
Review company-level records connected to Robert W. Wilkinson, Ph.D. before choosing the right outreach path.
About Robert W. Wilkinson, Ph.D.
An experienced, inspirational oncology drug hunter with deep understanding of small molecule and biologics drug discovery. Helped to bring many new drugs into clinical trials, including a key contributor to the nomination of 13 candidate drugs (CDs) and >10 investigational new drugs (INDs), and 2 launched drugs, Imfinzi® (PD-L1) and Imjudo® (CTLA-4).An authentic leader with a passion for building and leading high-functioning teams/organisations doing groundbreaking cancer research and drug discovery. Strong communicator with a proven ability to influence broadly at all levels, driving innovation and raising scientific quality whilst promoting a culture of trust and mutual integrity.A pioneer in Immuno-oncology (IO) drug discovery, at AstraZeneca/MedImmune proposed PD-L1 as a T cell checkpoint target and devised the drug discovery plan. Since the first approval in 2017, more than 150,000 patients have been treated with Imfinzi®. A core contributor of multiple other IO discovery programs, including Volrustomig (formerly MEDI5752) a bispecific antibody targeting PD1/CTLA-4, currently in Phase III. Recently, conceived AstraZeneca's NextGen IO scientific vision, led the global NextGen IO unit and translated its strategy into action, establishing a sustainable NextGen discovery pipeline.A track record of identifying and implementing novel drug platforms, spanning small molecules (antineoplastic kinase inhibitors, TLR agonists), fusion protein, mono- and bispecific antibodies, antibody-drug conjugates (ADCs), mRNA, and oncolytic virotherapy.An expert scientist in cancer biology, immunology, and drug discovery/translation having presented at national and international scientific meetings and been a co-author on over 85 peer-reviewed publications.
Robert W. Wilkinson, Ph.D.'s current company
Company context helps verify the profile and gives searchers a useful next step.
Robert W. Wilkinson, Ph.D. work experience
A career timeline built from the work history available for this profile.
Executive Director, Global Head Of Nextgen Immuno-Oncology (Io)
At AstraZeneca I conceived the NextGen IO scientific vision and led a global cross-functional team across UK and US sites. My role involved translating the strategy into tangible action plans. I assumed the responsibility of overseeing and managing the NextGen IO portfolio, ensuring seamless progression of projects from research and target selection.
Senior Director, Head Of Cambridge Oncology Research
Director, Head Of Cambridge Oncology Research
At Medimmune (a fully owned AstraZeneca group) led the cancer biologics discovery department in Cambridge. Directed projects from target discovery/proof-of-concept to IND filing and translational support, with a ‘commitment to excellence’. Helped to build a strong preclinical and clinical portfolio of novel immuno-oncology and antibody-drug conjugate.
Principal Scientist
At AstraZeneca formed a translational in vivo pharmacology team and delivered datasets to support the preclinical and clinical oncology small molecule pipeline. Worked across multiple areas of cancer biology, including cell cycle, growth factors, vascular modulation, invasion, and immunotherapy. Presented scientific findings at international conferences.
Team Leader, Head Of Discovery Medicine In Vivo (Uk)
Team Leader
Associate Team Leader
Team Leader/Post Doc
Robert W. Wilkinson, Ph.D. education
Doctor Of Philosophy - Phd, Experimental Immunology
Bachelor Of Science - Bsc (Hons), Human And Applied Biology
Frequently asked questions about Robert W. Wilkinson, Ph.D.
Quick answers generated from the profile data available on this page.
What company does Robert W. Wilkinson, Ph.D. work for?
Robert W. Wilkinson, Ph.D. works for Immunocore.
What is Robert W. Wilkinson, Ph.D.'s role at Immunocore?
Robert W. Wilkinson, Ph.D. is listed as Vice President, Head of Oncology Research at Immunocore I Focus on Immunotherapies I Passionate about science and delivering better medicines for cancer patients at Immunocore.
Where is Robert W. Wilkinson, Ph.D. based?
Robert W. Wilkinson, Ph.D. is based in Greater Cambridge Area, United Kingdom, United Kingdom while working with Immunocore.
What companies has Robert W. Wilkinson, Ph.D. worked for?
Robert W. Wilkinson, Ph.D. has worked for Immunocore, Astrazeneca, Medimmune, and Cancer Research Technology.
How can I contact Robert W. Wilkinson, Ph.D.?
You can use AeroLeads to view verified contact signals for Robert W. Wilkinson, Ph.D. at Immunocore, including work email, phone, and LinkedIn data when available.
What schools did Robert W. Wilkinson, Ph.D. attend?
Robert W. Wilkinson, Ph.D. holds Doctor Of Philosophy - Phd, Experimental Immunology from University Of Birmingham.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial